ライフサイエンスコーパス: antireflux

1 One of the proposed mechanisms for its antireflux action is that it reduces lower esophageal sp

2 Based on this mechanism of the antireflux actions of fundoplication, it might be possib

3 formed with low variation; MIS appendectomy, antireflux, and bariatric operations with medium variati

4 formed with low variation; MIS appendectomy, antireflux, and bariatric operations with medium variati

5 d: cholecystectomy, appendectomy, colectomy, antireflux, and bariatric.

6 d: cholecystectomy, appendectomy, colectomy, antireflux, and bariatric.

7 c antireflux therapies aiming at creating an antireflux barrier and reducing or eliminating the need

8 iculties in objectively proving an effective antireflux barrier.

9 toms suggestive of GER who do not respond to antireflux management may need to be treated for eosinop

10 nction as well as a compromise of the native antireflux mechanism.

11 of symptoms necessitating reintroduction of antireflux medication (ie, "intention to treat") and pos

12 was recurrence of reflux, defined as use of antireflux medication (proton pump inhibitors or histami

13 x recurrence; 393 (83.6%) received long-term antireflux medication and 77 (16.4%) underwent secondary

14 t difference between the need for restarting antireflux medication between both groups because of rec

15 bitor test results, long-term treatment with antireflux medication is warranted.

16 37 surgical patients reported that they used antireflux medications regularly (P<.001).

17 of obesity; common infectious diagnoses and antireflux medications were not.

18 isolated to the esophagus despite the use of antireflux medications.

19 records of 130 children undergoing a second antireflux operation for recurrent GER from January 1985

20 The addition of a Collis gastroplasty to an antireflux operation is an effective strategy in patient

21 tment of esophageal stricture and subsequent antireflux operations, SF-36 standardized physical and m

22 tic endoscopy, for example, may soon include antireflux operations.

23 Aggressive antireflux pharmacotherapy and, sometimes, surgery help

24 in patients with asthma or stridor following antireflux pharmacotherapy or surgery.

25 on appropriate indications for a concurrent antireflux procedure as well as alternatives to fundopli

26 hageal acid exposure, and the addition of an antireflux procedure is not required.

27 A safe and effective endoscopic antireflux procedure remains elusive.

28 n case series, many surgeons believe that an antireflux procedure should be added to the Heller myoto

29 views the most notable results of endoscopic antireflux procedure studies published in 2005.

30 Inclusion of an antireflux procedure, incidence of subsequent hernia rec

31 Laparoscopic myotomy, when combined with an antireflux procedure, provided better symptom relief (90

32 ux symptoms was unrelated to inclusion of an antireflux procedure.

33 verticulopexy with esophageal myotomy and an antireflux procedure.

34 bdominal exploration (nontrauma) (4.4%), and antireflux procedures (3.6%).

35 .2% MIS), vagotomy (1.8% MIS), and pediatric antireflux procedures (35.9% MIS); P < .001.

36 my 6.5%; colectomy 22.8%; gastrectomy 23.4%; antireflux procedures 23.4%; pancreatic resection 37.4%;

37 s the available literature on new endoscopic antireflux procedures along with other advances that giv

38 Antireflux procedures are most commonly performed in chi

39 Feeding access and associated antireflux procedures continue to be some of the most co

40 Additional endoscopic antireflux procedures have been introduced, although the

41 Endoscopic antireflux procedures have generated much interest among

42 n that many surgeons will not perform enough antireflux procedures to become familiar with its diagno

43 Sac removal, crural repair, and antireflux procedures were performed (72 Nissen, 27 Coll

44 rial was performed to determine which of two antireflux procedures, a complete wrap (Nissen) or a 200

45 antly open to MIS approach for appendectomy, antireflux procedures, thoracic wedge resection, and par

46 ization should be a part of all laparoscopic antireflux procedures.

47 Fifteen patients underwent antireflux procedures.

48 A study on an antireflux stent will not measurably change the current

49 gus (BE) are frequently offered laparoscopic antireflux surgery (LARS) to treat symptoms.

50 common in the learning curve of laparoscopic antireflux surgery (LARS).

51 n regarding "success" rates for laparoscopic antireflux surgery (LARS).

52 Among all 2655 patients who underwent antireflux surgery (median age, 51.0 years; interquartil

53 ectomy (OR: 2.0; 95% CI: 1.2-3.3; P < 0.01), antireflux surgery (OR: 24.7; 95% CI: 2.6-580.9; P < 0.0

54 ithout fistula (P = 0.03), previous multiple antireflux surgery (P = 0.04), esophageal dilation (P =

55 ing 2655 patients who underwent laparoscopic antireflux surgery according to the Swedish Patient Regi

56 Since 1991, all patients undergoing antireflux surgery across 2 hospital sites have been fol

57 Anatomic fundoplication failure occurs after antireflux surgery and may be more common in the learnin

58 There was no difference in EAC risk between antireflux surgery and medical treatment in GERD patient

59 Laparoscopic antireflux surgery and repair of small hiatal hernias ar

60 risk of reflux recurrence after laparoscopic antireflux surgery and to identify risk factors for recu

61 up, 53 patients (76%) underwent laparoscopic antireflux surgery because of symptoms refractory to med

62 ased case-control study was nested within an antireflux surgery cohort from the Swedish Patient Regis

63 From 14,102 patients in the total antireflux surgery cohort, 55 cases and 240 controls wer

64 EAC risk remained elevated in patients after antireflux surgery compared with the background populati

65 otal of 345 patients undergoing laparoscopic antireflux surgery completed at least one questionnaire

66 e overrepresented among patients who despite antireflux surgery develop esophageal adenocarcinoma.

67 The EAC risk after antireflux surgery does not seem to revert to that of th

68 Primary laparoscopic antireflux surgery due to gastroesophageal reflux diseas

69 sideration should be given to more effective antireflux surgery for transplants, with subsequent test

70 that preventing gastroesophageal reflux with antireflux surgery halts the progression of BE, often be

71 Antireflux surgery has become more popular with advanced

72 Reflux recurrence after laparoscopic antireflux surgery has not been assessed in a long-term

73 Antireflux surgery has the potential to stop reflux and

74 Antireflux surgery in patients with Barrett's esophagus

75 Concerns about laparoscopic antireflux surgery include the frequent appearance of tr

76 As a result, laparoscopic antireflux surgery is a common surgical procedure.

77 Studies continue to show that laparoscopic antireflux surgery is a cost-effective treatment option

78 tion, the barium esophagram before and after antireflux surgery is a critical examination in patients

79 Laparoscopic antireflux surgery is a very effective and long-lasting

80 Laparoscopic [correction of Laparascopic] antireflux surgery is an alternative strategy, but neith

81 Laparoscopic antireflux surgery is an effective therapy for patients

82 Antireflux surgery is associated with regression of Barr

83 The management of patients who fail antireflux surgery is complex and not well codified.

84 e aim of this study was to determine whether antireflux surgery is more effective in producing loss o

85 Antireflux surgery is often necessary, but a 10% failure

86 LARS has increased the frequency with which antireflux surgery is performed for the treatment of gas

87 Loss of intestinal metaplasia after antireflux surgery is rare in patients with Barrett's, b

88 Antireflux surgery is safe and effective in patients wit

89 The entity of the short esophagus in antireflux surgery is seldom discussed in the laparoscop

90 and characterization of hypomotility before antireflux surgery may be less important than systematic

91 BRAVO wireless pH monitoring, suggests that antireflux surgery may halt the progression of Barrett's

92 Antireflux surgery may prevent EAC better than medical t

93 To assess the long-term efficacy of antireflux surgery on Barrett's esophagus (BE) using BRA

94 A question exists as to whether antireflux surgery reduces this risk.

95 ght explain the lack of protective effect of antireflux surgery regarding risk of developing esophage

96 sophageal motor dysfunction to outcomes from antireflux surgery remains incompletely understood.

97 This study suggests that antireflux surgery should not be advised with the expect

98 Studies evaluating ileal pouch formation and antireflux surgery showed conflicting results.

99 phageal disease allows the surgeon to tailor antireflux surgery to esophageal body function and follo

100 agus, and 2 studies comparing EAC risk after antireflux surgery to the background population.

101 The pooled IRR in patients after antireflux surgery was 0.76 (95% CI 0.42-1.39) compared

102 Laparoscopic antireflux surgery was associated with a relatively high

103 Hospital volume of antireflux surgery was not associated with risk of reflu

104 Antireflux surgery was performed in 18 patients (17%).

105 prospectively collected research database of antireflux surgery was performed to identify all patient

106 The outcome of antireflux surgery was studied in 97 patients with Barre

107 with BE and at least 5 years follow up after antireflux surgery were identified.

108 ophageal peristalsis undergoing laparoscopic antireflux surgery were prospectively studied.

109 entified 10 studies comparing EAC risk after antireflux surgery with nonoperated GERD patients, inclu

110 patients who underwent primary laparoscopic antireflux surgery, 17.7% experienced recurrent gastroes

111 on, 8% were undernourished, 41% had received antireflux surgery, and 41% presented with GERD symptoms

112 2011 using the keywords achalasia, myotomy, antireflux surgery, and fundoplication.

113 laparoscopic appendectomy, cholecystectomy, antireflux surgery, and gastric bypass between 2002 and

114 ss level who underwent open cholecystectomy, antireflux surgery, and gastric bypass had a greater ris

115 Antireflux surgery, as opposed to medical therapy, may i

116 motility assessments in patients undergoing antireflux surgery, as peristaltic features do not solel

117 likely to have recurrent reflux after their antireflux surgery, compared with those who had not (OR:

118 eration should not alter the indications for antireflux surgery, especially for patients with atypica

119 After antireflux surgery, most patients with Barrett's enjoy l

120 ageal adenocarcinoma more than 5 years after antireflux surgery, whereas randomly selected controls w

121 ported high rates of reflux recurrence after antireflux surgery, which may have contributed to a decl

122 be approximately 10% of patients undergoing antireflux surgery.

123 al metaplasia of the esophagus or cardia had antireflux surgery.

124 induced asthma responds convincingly only to antireflux surgery.

125 equivalent in efficacy to open techniques of antireflux surgery.

126 uiring long-term medication use or secondary antireflux surgery.

127 edication and 77 (16.4%) underwent secondary antireflux surgery.

128 ptor antagonists for >6 months) or secondary antireflux surgery.

129 ss index (BMI), tobacco smoking, and type of antireflux surgery.

130 d better elucidate those who will respond to antireflux surgery.

131 pport for any cancer-protective effect after antireflux surgery.

132 regarding age, sex, and calendar year of the antireflux surgery.

133 reatment can be achieved with medication and antireflux surgery; however the possible preventive effe

134 Several endoscopic antireflux therapies aiming at creating an antireflux ba

135 reports may show some advantage of surgical antireflux therapy in reducing the risk of adenocarcinom

136 antly improves quality of life, and surgical antireflux therapy may gradually cause regression of the

137 scale scores, and overall satisfaction with antireflux therapy.

138 re sensitive tool for judging the success of antireflux therapy.